BCMA

BCMA

BCMA Overview

Molecule Name
B-cell maturation protein
Synonyms
TNFRSF17,CD269,BCM,BCMA
Drug Development Progress
Drugs in Clinical Trials151
Approved Drugs8
Highest Development StageApproved
Target Synonym
B-Cell Maturation Protein,B-Cell Maturation Factor,B Cell Maturation Antigen,CD269 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 17,TNFRSF17,TNFRSF13A,CD269,BCM,BCMA,TNF Receptor Superfamily Member 17,Tumor Necrosis Factor Receptor Superfamily, Member 17,B-Cell Maturation Antigen
Background
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

BCMA Product List

Species
  • Human(20)
  • Cynomolgus / Rhesus macaque(5)
  • Mouse(3)
  • Canine(1)
  • Rabbit(1)
  • Rat(1)
Tag
  • His Tag(19)
  • Fc Tag(4)
  • Fc Tag & Avi Tag(3)
  • His Tag & Avi Tag(2)
  • Llama IgG Fc Tag(2)
  • Mouse IgG Fc Tag(1)
Host
  • HEK293(31)
Conjugate
  • Unconjugated(16)
  • Biotin-labeled(5)
  • FITC Labeled(3)
  • APC Labeled(2)
  • PE Labeled(2)
  • AF488 Labeled(1)
  • AF555 Labeled(1)
  • AF647 Labeled(1)
Grade
  • RUO(27)
  • PG (pre-GMP)(4)
Low Endotoxin
  • Yes(3)
  • No(28)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
BCMA
HOTDMF
BCA-HF254
FITC-Labeled Human BCMA / TNFRSF17 Protein, Fc Tag
Human
HEK293
SDS-PAGE
ELISAFlow

$380.00

25ug
BCMA
Biotinylated Human BCMA / TNFRSF17 Protein, His,Avitag™, premium grade
Human
HEK293
HPLCSDS-PAGE
ELISABLIFlowTR-FRET

$360.00

25ug
BCMA
Human BCMA / TNFRSF17 Protein, His Tag, premium grade (Mass Spec verified)
Human
HEK293
HPLCSDS-PAGE
ELISASPRBLIFlow

$455.00

100ug
BCMA
HOTDMF
BCA-HP2H2
PE-Labeled Human BCMA / TNFRSF17 Protein, His Tag (Site-specific conjugation)
Human
HEK293
Flow

$420.00

25tests
BCMA
Human BCMA / TNFRSF17 Protein, Fc Tag, premium grade
Human
HEK293
MALSSDS-PAGE
ELISABLIFlow

$415.00

100ug
BCMA
AvitagDMF
BC7-H82F0
Biotinylated Human BCMA / TNFRSF17 Protein, Fc,Avitag™, premium grade
Human
HEK293
MALSSDS-PAGE
ELISAFlowTR-FRET

$260.00

25ug
BCMA
Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc Tag (MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$360.00

100ug
BCMA
Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Llama IgG2b Fc Tag, low Endotoxin (MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$360.00

100ug
BCMA
Canine BCMA / TNFRSF17 Protein, His Tag (MALS verified)
Canine
HEK293
MALSSDS-PAGE
ELISA

$360.00

100ug
BCMA
Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His Tag (HPLC verified)
Cynomolgus / Rhesus macaque
HEK293
HPLCSDS-PAGE
ELISA

$415.00

100ug
You Have Viewed 1-10 Of 31 Results
  • 1
  • 2
  • 3
  • 4

Can’t find what you need?

Submit your requirements and our technical
team will help.

FAQ

How does ACROBiosystems support the development of BCMA-targeted CAR-T therapies?

ACROBiosystems provides a comprehensive portfolio of products supporting every stage of BCMA-targeted CAR-T development, including recombinant BCMA proteins, fluorescently labeled proteins, CAR detection reagents, ActiveMax® BCMA magnetic beads, and analytical tools. These solutions enable antibody screening, CAR detection, cell enrichment, functional evaluation, and quality control, providing an integrated platform to accelerate cell therapy research and development.

Why is it important to use high-quality recombinant BCMA proteins in CAR-T research?

The native conformation and biological activity of recombinant BCMA proteins directly influence the interaction between CAR molecules and their target antigen. Using recombinant BCMA proteins with native-like structure, high purity, and excellent batch-to-batch consistency helps minimize experimental variability, improve reproducibility, and enhance the reliability of CAR-T screening and characterization studies.

What applications do recombinant BCMA proteins support?

Recombinant BCMA proteins support a broad range of research and analytical applications, including: CAR candidate screening Anti-BCMA antibody discovery CAR expression detection CAR-T cell binding assays Affinity analysis using ELISA, SPR, and BLI Flow cytometry (FACS) Functional and mechanism-of-action studies These applications span the entire workflow from basic research to analytical development and CMC studies.

Why are recombinant BCMA proteins important tools for CAR-T development?

High-quality recombinant BCMA proteins play a critical role throughout CAR-T development. They are widely used for CAR candidate screening, antibody discovery, cell-binding assays, CAR expression analysis, functional characterization, and potency studies. Recombinant proteins with high biological activity, high purity, and native-like conformation help generate more reliable and reproducible experimental results, ultimately improving the efficiency of CAR-T research.

Why do BCMA-targeted CAR-T therapies achieve such high response rates?

BCMA-targeted CAR-T cells are genetically engineered to specifically recognize and eliminate BCMA-positive multiple myeloma cells. Following infusion, these engineered T cells expand in vivo, selectively kill tumor cells, and may provide long-term immune surveillance. As a result, BCMA CAR-T therapies have demonstrated impressive overall response rates (ORR) and complete response (CR) rates in patients with relapsed or refractory multiple myeloma.

What are the major therapeutic approaches targeting BCMA?

Current BCMA-targeted therapies can be broadly classified into three major modalities: BCMA-targeted CAR-T cell therapies BCMA-targeted bispecific antibodies (BsAbs) BCMA-targeted antibody-drug conjugates (ADCs) Each approach offers distinct advantages. CAR-T therapies can induce deep and durable responses, bispecific antibodies provide an off-the-shelf treatment option, and ADCs deliver potent cytotoxic agents directly to BCMA-expressing tumor cells.

What role does BCMA play in multiple myeloma?

BCMA binds to its ligands, APRIL and BAFF, activating downstream signaling pathways such as NF-κB that promote plasma cell survival, proliferation, and immune evasion. Because multiple myeloma cells rely on BCMA signaling for growth and survival, targeting BCMA has become one of the most effective therapeutic strategies for treating MM.

What is BCMA, and why is it an ideal therapeutic target for multiple myeloma (MM)?

B-cell Maturation Antigen (BCMA) is a member of the tumor necrosis factor receptor (TNFR) superfamily. It is primarily expressed on mature B cells and plasma cells, with limited expression in normal tissues, while remaining highly expressed on the majority of multiple myeloma (MM) cells. Its restricted tissue distribution and stable tumor expression make BCMA one of the most attractive targets for the development of CAR-T cell therapies, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs).
Asset Licensing Opportunity

Antibody Project Trading Platform

Project NameProject StageMolecule TypeMolecule SourceDisease AreaIndication
BCMA VHH - 01LeadMonoclonalNanobodyHematological MalignancyMultiple myeloma
Project Name
BCMA VHH - 01
Project Stage
Lead
Molecule Type
Monoclonal
Molecule Source
Nanobody
Disease Area
Hematological Malignancy
Indication
Multiple myeloma
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University)Phase 3 ClinicalThe First Affiliated Hospital Of Soochow University
Leukemia; Multiple Myeloma
Details
Anitocabtagene autoleucelKite-772; CART-ddBCMAPhase 3 ClinicalArcellx Inc
Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Multiple Myeloma; Muscle Weakness; Muscular Diseases; Myasthenia Gravis; Neuromuscular Manifestations
Details
EtentamigTNB-383B; ABBV-383Phase 3 ClinicalTeneoOne Inc
Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Waldenstrom Macroglobulinemia
Details
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian)Descartes-08Phase 3 ClinicalCartesian Therapeutics Inc
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Anti-synthetase Syndrome; Dermatomyositis; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis
Details
GC-012FAZD0120; GC-012F; GC012F; AZD-0120Phase 3 ClinicalGracell Biotechnologies (Shanghai) Co Ltd
Amyloidosis; Arthritis, Rheumatoid; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Multiple Sclerosis; Myasthenia Gravis; Myositis; Scleroderma, Systemic
Details
BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital)Phase 3 ClinicalPeking University People'S Hospital
Acquired thrombotic thrombocytopenic purpura; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Behcet Syndrome; Carcinoma, Transitional Cell; Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic; Myositis; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome
Details
RamantamigJNJ-79635322; JNJ-5322Phase 3 ClinicalJanssen Research & Development Llc
Multiple Myeloma
Details
VelinotamigGR-1803Phase 3 ClinicalChongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd
Autoimmune Diseases; Lupus Erythematosus, Systemic; Multiple Myeloma
Details
GamgertamigCM-336; OM336Phase 3 ClinicalKeymed Biosciences Co Ltd
Amyloidosis; Anemia, Hemolytic, Autoimmune; Cytopenia; Evans syndrome; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome; Skin Diseases, Vesiculobullous
Details
BCMA CAR-T Cells (Pregene)PRG-1801; GLPG-5301; DRL-1801Phase 2 ClinicalShenzhen Pregene Biopharma Co Ltd
Immunoglobulin G4-Related Disease; Lupus Nephritis; Multiple Myeloma; Purpura, Thrombocytopenic, Idiopathic
Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology)BCMA-CART; HR003Phase 2 ClinicalHrain Biotechnology Co Ltd
Multiple Myeloma
Details
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech)Phase 2 ClinicalChongqing Precision Biotechnology Co Ltd
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma
Details
BCMA CAR-T cell therapy (Chongqing Precision Biotech)Phase 2 ClinicalChongqing Precision Biotechnology Co Ltd
Multiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma
Details
Anti-BCMA chimeric antigen receptor T cell therapy (Shanghai Unicar-Therapy Bio-medicine Technology)Phase 2 ClinicalShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Leukemia; Multiple Myeloma
Details
C-CAR088C-CAR088Phase 2 ClinicalCellular Biomedicine (Shanghai) Co Ltd
Multiple Myeloma
Details
Orvacabtagene autoleucelET140-CAR; MCARH-171; JCARH-125; FCARH-143; ET-140Phase 2 ClinicalFred Hutchinson Cancer Research Center
Multiple Myeloma
Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army)Phase 2 ClinicalPeople'S Liberation Army General Hospital Military Service
Multiple Myeloma
Details
KQ-2003KQ-2003; KQ2003Phase 2 ClinicalShanghai Keqi Pharmaceutical Technology Co Ltd
Multiple Myeloma; POEMS Syndrome; Solid tumours
Details
Pamlectabart tismanitinHDP101-ATAC; HDM2027; HDP-101Phase 2 ClinicalHeidelberg Pharma AG
Hematologic Diseases; Multiple Myeloma; Paraproteinemias
Details
Anti BCMA CAR-T cells therapy (Minsk Scientific-Practical Center For Surgery, Transplantation And Hematology)Phase 2 ClinicalMinsk Scientific-Practical Center For Surgery, Transplantation And Hematology
Multiple Myeloma
Details
Anti-BCMA-CD19 CAR-T cells therapy (Pla General Hospital)Phase 2 ClinicalPla General Hospital
Autoimmune Diseases; Immunoglobulin G4-Related Disease
Details
BCMA CAR-T Cell Therapy (Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)
Multiple Myeloma
Details
BCMA/GPRC5D targeting chimeric antigen receptor T cell therapy (Essen Biotech)Phase 2 ClinicalEssen Biotech
Multiple Myeloma
Details
SL-1703SL1703; SL-1703Phase 2 ClinicalHebei Senlang Biological Technology Co Ltd
Lupus Nephritis; Multiple Myeloma; Scleroderma, Systemic
Details
VonsetamigREGN-5459Phase 2 ClinicalRegeneron Pharmaceuticals Inc
Lupus Nephritis; Multiple Myeloma; Renal Insufficiency, Chronic
Details
QT-019BQT-019BPhase 2 ClinicalHangzhou Qihan Biotechnology Co Ltd
Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Lupus Erythematosus, Systemic; Myasthenia Gravis
Details
anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)
Multiple Myeloma
Details
ICG-318ICG-318; ICG318Phase 2 ClinicalSonghe Immunobiological Medical (Shenzhen) Co Ltd
Lupus Erythematosus, Systemic; Lupus Nephritis
Details
BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital)Phase 2 ClinicalShenzhen University General Hospital
Multiple Myeloma
Details
Chimeric Antigen Receptor Modified T Cells Targeting BCMA(The First Affiliated Hospital of Xiamen University)Phase 2 ClinicalThe First Affiliated Hospital Of Xiamen University
Multiple Myeloma
Details
BCD-248BCD-248Phase 2 ClinicalBIOCAD JSC
Multiple Myeloma
Details
SENL-103SENL-103; S-103Phase 2 ClinicalHebei Senlang Biological Technology Co Ltd
Amyloidosis; Multiple Myeloma; Multiple Sclerosis; Myasthenia Gravis
Details
Nanobody-based biepitope BCMA-targeting CAR-T cells therapy(Tahoe Chunyu Biotechnology)Phase 2 ClinicalHebei Tahoe Chunyu Biotechnology Co Ltd
Leukemia, Plasma Cell; Multiple Myeloma
Details
CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute)Phase 2 ClinicalShenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of Health
Multiple Myeloma; Plasmacytoma
Details
Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech)Phase 2 ClinicalEssen Biotech
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoimmune Diseases; Granulomatosis with Polyangiitis; Lupus Erythematosus, Systemic; Lupus Nephritis; Microscopic Polyangiitis; Myositis; Scleroderma, Systemic; Sjogren's Syndrome
Details
Anti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences)Phase 2 ClinicalShahid Beheshti University Of Medical Sciences
Multiple Myeloma
Details
C-CAR168C-CAR168Phase 2 ClinicalCellular Biomedicine (Shanghai) Co Ltd
Autoimmune Diseases; Encephalitis; Lupus Erythematosus, Systemic; Lupus Nephritis; Multiple Sclerosis; Muscular Diseases; Myasthenia Gravis; Neuromyelitis Optica; Scleroderma, Systemic; Stiff-Person Syndrome
Details
IBI-3003IBI3003; IBI-3003Phase 2 Clinical
Multiple Myeloma
Details
BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene)Phase 2 ClinicalGuangzhou Bio-Gene Technology Co Ltd
Multiple Myeloma
Details
CART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital)Phase 2 ClinicalInstitute Of Hematology & Blood Diseases Hospital
Multiple Myeloma
Details
MBS-314MBS-314Phase 2 ClinicalBeijing Mabworks Biotech Co Ltd
Multiple Myeloma
Details
BelantamabGSK2857914; GSK-2857914Phase 2 ClinicalGlaxosmithkline Plc
Autoimmune Diseases; Multiple Myeloma
Details
SNC-102 (Shanghai Simnova Biotechnology)SNC102; CART-BCMAPhase 2 ClinicalShanghai Simnova Biotechnology Co Ltd
Multiple Myeloma
Details
Anti-BCMA/GPRC5D Bispecific CAR T cell therapy (Shanghai YaKe Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co Ltd
Multiple Myeloma
Details
TQB-2934TQB2934; TQB-2934Phase 2 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Amyloidosis; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Neoplasms, Plasma Cell
Details
CAR-BCMA(Sheba Medical Center)Phase 2 ClinicalSheba Medical Center, Israel
Multiple Myeloma
Details
ARI-0002hARI-0002hPhase 2 ClinicalInstituto De Salud Carlos Iii
Multiple Myeloma
Details
Descartes-11Descartes-11; Descartes-011Phase 2 ClinicalCartesian Therapeutics Inc
Multiple Myeloma
Details
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital)Phase 2 ClinicalShenzhen University General Hospital
Multiple Myeloma
Details
F-182112F182112; F-182112Phase 2 ClinicalShandong New Time Pharmaceutical Co Ltd
Lupus Erythematosus, Systemic; Multiple Myeloma
Details
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical)Phase 2 ClinicalShandong New Time Pharmaceutical Co Ltd
Lupus Erythematosus, Systemic; Multiple Myeloma
Details
Revlucabtagene AutoleucelHBI-0101; NXC-201Phase 2 ClinicalHadassah Medical Organization, Immix Biopharma Inc
Arthritis, Rheumatoid; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Multiple Myeloma; Myositis; Scleroderma, Systemic
Details
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co Ltd
Multiple Myeloma; Neoplasms
Details
PodentamigHPN-217; BCMA TriTACPhase 1 ClinicalAbbvie Inc, Harpoon Therapeutics
Multiple Myeloma
Details
ACTR 087/SEA BCMA combination therapyPhase 1 ClinicalUnum Therapeutics Inc
Multiple Myeloma
Details
bb-21217bb-21217Phase 1 ClinicalBristol-Myers Squibb Company, Genetix Biotherapeutics Inc
Multiple Myeloma
Details
AMG-224AMG-224Phase 1 ClinicalAmgen Inc
Multiple Myeloma
Details
Nendocabtagene onogedleucelALLO-715Phase 1 ClinicalCellectis Sa
Multiple Myeloma
Details
AlnuctamabEM-901; BMS-986349; CC-93269Phase 1 ClinicalEngmab Ag
Lupus Erythematosus, Systemic; Multiple Myeloma
Details
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)Phase 1 ClinicalThe First Affiliated Hospital Of Nanchang University
Multiple Myeloma
Details
PavurutamabAMG-701Phase 1 ClinicalAmgen Inc
Multiple Myeloma
Details
CART-BCMAMTV-273; CART-BCMAPhase 1 ClinicalUniversity Of Pennsylvania
Kidney Failure, Chronic; Multiple Myeloma; Rejection of renal transplantation; Renal Insufficiency
Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics)Phase 1 ClinicalIcell Gene Therapeutics (Int'L) Ltd
Lupus Erythematosus, Systemic; Multiple Myeloma; Pancytopenia; Waldenstrom Macroglobulinemia
Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology)Phase 1 ClinicalShengyan Pharmaceutical Technology
Multiple Myeloma
Details
SA102-CAR-TSA-102; SA102Phase 1 ClinicalWuhan Sian Biotechnology Co Ltd
Multiple Myeloma
Details
DXC-009DXC-009Phase 1 ClinicalHangzhou Dac Biotech Company Ltd
Multiple Myeloma
Details
ACLX-001ACLX-001Phase 1 ClinicalArcellx Inc
Multiple Myeloma
Details
CB-011CB-011Phase 1 ClinicalCaribou Biosciences Inc
Multiple Myeloma
Details
FT-576FT-576Phase 1 ClinicalFate Therapeutics Inc, University Of Minnesota
Bone Marrow Neoplasms; Multiple Myeloma
Details
P-BCMA-ALLO1P-BCMA-ALLO1; RG-6538Phase 1 ClinicalJanssen Biotech Inc, Transposagen Biopharmaceuticals Inc
Multiple Myeloma
Details
Allogeneic CD19/BCMA-targeted CAR-γδT cell therapy (Institute Of Hematology & Blood Diseases Hospital)Phase 1 ClinicalInstitute Of Hematology & Blood Diseases Hospital
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lupus Erythematosus, Systemic; Myositis; Scleroderma, Systemic; Thrombocytopenia
Details
BCMA-Targeted CAR T-Cell therapy (Chulalongkorn University)Phase 1 ClinicalChulalongkorn University
Multiple Myeloma
Details
CAR BCMA-CD70-T cells therapy (The Fifth Medical Center Of Pla General Hospital)Phase 1 ClinicalThe Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital)
Neoplasms, Plasma Cell
Details
CD19/BCMA in vivo CAR-T cell therapy (West China Hospital Of Sichuan University)Phase 1 ClinicalWest China Hospital Of Sichuan University
Autoimmune Diseases
Details
O&D-001O&D-001Phase 1 ClinicalO&D BioTech Group Co Ltd
Multiple Myeloma
Details
Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy (Beijing Gao Boren Hospital)Phase 1 ClinicalBeijing Gao Boren Hospital Co Ltd
Anemia, Hemolytic, Autoimmune; Lupus Erythematosus, Systemic; Multiple Sclerosis; Scleroderma, Systemic; Sjogren's Syndrome
Details
IASO-206IASO206; IASO-206Phase 1 ClinicalInstitute Of Hematology & Blood Diseases Hospital
Multiple Myeloma
Details
UCAR T-cell therapy (The Children'S Hospital, Zhejiang University School Of Medicine)Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of Medicine
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoimmune Diseases; Glomerulonephritis, IGA; Lupus Erythematosus, Systemic; Nephrosis; Scleroderma, Systemic
Details
Fully-Human Anti-BCMA CAR therapy (NIH)Phase 1 ClinicalNational Cancer Institute
Multiple Myeloma
Details
NPB5005-V283NPB5005-V283Phase 1 ClinicalNeomics Pharmaceuticals LLC
Multiple Myeloma
Details
CAR19-BCMA dual-target CAR-T cell therapy (Tahoe Chunyu Biotechnology)Phase 1 ClinicalHebei Tahoe Chunyu Biotechnology Co Ltd
Multiple Myeloma
Details
TPST-2003TPST-2003Phase 1 ClinicalFactor Bioscience Inc
Multiple Myeloma
Details
Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells therapy (Rui Therapeutics)KN-3601; KN3601Phase 1 ClinicalShenzhen Rui Therapeutics Co Ltd
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic; Nephrosis; Scleroderma, Systemic; Sjogren's Syndrome
Details
KT-501KT501; KT-501Phase 1 ClinicalKali Therapeutics Inc
Arthritis, Rheumatoid
Details
Fully Human BCMA-Targeted Chimeric Antigen Receptor Autologous T-Cell therapy (Institute of Hematology & Blood Diseases Hospital)CT103dPhase 1 ClinicalInstitute Of Hematology & Blood Diseases Hospital
Leukemia, Plasma Cell; Multiple Myeloma
Details
Allogeneic, Umbilical Cord Blood-derived, Dual-targeting BCMA/CD19 CAR-T Therapy (Ucello)Phase 1 ClinicalUcello Therapeutics Co Ltd
Lupus Erythematosus, Systemic; Multiple Myeloma
Details
QM-103QM-103; QM103Phase 1 ClinicalBeijing Qimai Yonghua Biotechnology Co Ltd
Multiple Myeloma
Details
RN-1201RN-1201; RN1201Phase 1 ClinicalThe First Affiliated Hospital Of Soochow University
Thrombocytopenia
Details
OriV-508OriV508; OriV-508Phase 1 ClinicalWuhan Medical Care Center For Women And Children
Lymphoma, Non-Hodgkin; Multiple Myeloma
Details
Meta10-BCMAMeta10-BCMAPhase 1 ClinicalAnhui Provincial Hospital
Immunoglobulin Light-chain Amyloidosis; Leukemia, Plasma Cell; Multiple Myeloma
Details
SL-0439SL0439; SL-0439Phase 1 ClinicalHebei Senlang Biological Technology Co Ltd
Multiple Myeloma
Details
RN-1101 (Rui Therapeutics)RN-1101Phase 1 ClinicalShenzhen Rui Therapeutics Co Ltd
Lymphoma, B-Cell; Multiple Myeloma
Details
CAR19BCMA-T cells therapy(The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital))Phase 1 ClinicalThe Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital)
Neoplasms, Plasma Cell
Details
Anti-CD19/BCMA CAR NK cells therapy(The Children's Hospital of Zhejiang University School of Medicine)KN5601; KN-5601Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of Medicine
Arthritis; Autoimmune Diseases; Glomerulonephritis, IGA; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Mucocutaneous Lymph Node Syndrome; Nephrosis; Rheumatic Diseases
Details
RD06-05RD06-05Phase 1 ClinicalNanjing Bioheng Biotech Co Ltd
Anemia, Hemolytic, Autoimmune; Anti-Glomerular Basement Membrane Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Encephalitis; Evans syndrome; Glomerulonephritis; Graves Disease; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Multiple Sclerosis; Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic; Scleroderma, Systemic
Details
CT-0596CT-0596; CT0596Phase 1 ClinicalCarsgen Biomedicine (Shanghai) Co Ltd
Leukemia, Plasma Cell; Multiple Myeloma
Details
68Ga-BC168Ga-BC1Phase 1 ClinicalThe First Affiliated Hospital Of Beijing University
Multiple Myeloma; Neoplasms, Plasma Cell
Details
UF-KURE-BCMA CAR-T Cells therapy(University Hospitals Cleveland Medical Center)Phase 1 ClinicalUniversity Hospitals Cleveland Medical Center
Multiple Myeloma
Details
ESO-T01ESO-T01Phase 1 ClinicalEsoBiotec SA
Multiple Myeloma
Details
REVO-UWD-00BREVO-UWD-00B; UWD-00BPhase 1 ClinicalWondercel Therapeutics Co Ltd
Multiple Myeloma
Details
Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine)Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of Medicine
Lupus Erythematosus, Systemic; Nephrosis
Details
PRG-2311PRG-2311Phase 1 ClinicalShenzhen Pregene Biopharma Co Ltd
Immunoglobulin G4-Related Disease; Lupus Nephritis
Details
BZE-2204BZE2204; BZE-2204Phase 1 ClinicalShanghai Cell Therapy Group Co Ltd
Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic
Details
OL-101OL-101Phase 1 ClinicalOverland Pharmaceuticals (Shanghai) Co Ltd
Multiple Myeloma
Details
Anti-CD19/BCMA CAR T-cell therapy(YaKe Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang University
Lupus Erythematosus, Systemic; Lupus Nephritis
Details
QLS-4131QLS-4131; QLS4131Phase 1 ClinicalQilu Pharmaceutical Co Ltd
Lupus Erythematosus, Systemic; Multiple Myeloma
Details
Zirconium-89 belantamab89Zr-GSK2857914Phase 1 ClinicalGlaxosmithkline Plc
Multiple Myeloma; Neoplasms
Details
RD-140RD140Phase 1 ClinicalNanjing Iaso Biotherapeutics Co Ltd
Leukemia, Plasma Cell; Multiple Myeloma
Details
BCMA CAR-NK (Hrain Biotechnology)HR012Phase 1 ClinicalHrain Biotechnology Co Ltd
Leukemia, Plasma Cell; Multiple Myeloma
Details
CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital)Phase 1 ClinicalWuhan Union Hospital
Lupus Erythematosus, Systemic
Details
SYS-6020SYS6020; SYS-6020Phase 1 ClinicalCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis
Details
KLN-1010KLN-1010Phase 1 ClinicalKelonia Therapeutics Inc
Blood Protein Disorders; Hemostatic Disorders; Immune System Diseases; Immunoproliferative Disorders; Lymphoproliferative Disorders; Multiple Myeloma; Neoplasms; Paraproteinemias; Vascular Diseases
Details
The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine)FKC-288; FKC288Phase 1 ClinicalNanjing University School Of Medicine
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, Membranous; Immunoglobulin G4-Related Disease; Lupus Nephritis
Details
YKST-02YKST02; YKST-02Phase 1 ClinicalExcyte Biopharma Ltd
Multiple Myeloma
Details
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics)BMS-986453Phase 1 ClinicalJuno Therapeutics Inc
Multiple Myeloma
Details
SIM-0500SIM-0500; SIM0500Phase 1 ClinicalSimcere Pharmaceutical Group Ltd
Bone Marrow Neoplasms; Multiple Myeloma
Details
Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering)Phase 1 ClinicalHualan Genetic Engineering (Henan) Co Ltd
Multiple Myeloma
Details
BCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics)CBG-002 CAR-TPhase 1 ClinicalCarbiogene Therapeutics Co Ltd
Multiple Myeloma
Details
BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma)SWK001; SWK-001Phase 1 ClinicalHunan Siweikang Pharmaceutical Co Ltd
Multiple Myeloma
Details
Anti-BCMA CAR T (Nanjing Kati Medical Technology)Phase 1 ClinicalNanjing Kati Medical Technology Co Ltd
Multiple Myeloma
Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)Phase 1 ClinicalActavis Inc, Eugia Pharma Specialities Ltd
Multiple Myeloma
Details
LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co)Phase 1 Clinical
Multiple Myeloma
Details
BRL-302BRL-302Phase 1 ClinicalBRL Medicine Inc
Autoimmune Diseases; Lupus Nephritis; Multiple Sclerosis; Myasthenia Gravis; Neuromyelitis Optica; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours
Details
MCARH-125MCARH-125Phase 1 ClinicalMemorial Sloan Kettering Cancer Center
Multiple Myeloma
Details
ISB-2001ISB-2001; ABBV-2001Phase 1 ClinicalIchnos Sciences Sa
Multiple Myeloma
Details
OriC-321OriC-321; Ori-C-321Phase 1 ClinicalOriCell Therapeutics Co Ltd, Zhejiang University
Multiple Myeloma
Details
HY-027HY-027Phase 1 ClinicalJuventas Cell Therapy Ltd
Multiple Myeloma
Details
MEDI-2228MEDI-2228Phase 1 ClinicalMedimmune Llc
Multiple Myeloma
Details
IBI-346IBI-346Phase 1 Clinical
Multiple Myeloma
Details
BCMA-NKEBCMA-NKEPhase 1 ClinicalBristol-Myers Squibb Company
Multiple Myeloma
Details
KJ-C2111CT-0590; KJ-C2111Phase 1 ClinicalCARsgen Therapeutics Holdings Ltd
Leukemia, Plasma Cell; Multiple Myeloma
Details
PHE-885PHE-885Phase 1 ClinicalNovartis Pharma Ag
Hematologic Neoplasms; Multiple Myeloma
Details
MCM-998MCM-998; LXG-250Phase 1 ClinicalNovartis Pharma Ag
Multiple Myeloma
Details
ALLO-605ALLO-605; ALLO605Phase 1 ClinicalCellectis Sa, Overland Pharmaceuticals (Shanghai) Co Ltd
Multiple Myeloma
Details
AUTO-8AUTO-8Phase 1 ClinicalAutolus Therapeutics Plc
Multiple Myeloma
Details
CizutamigEMB-06; CND-106; CN106Phase 1 ClinicalShanghai Epimab Biotherapeutics, Inc
Colitis, Ulcerative; Food Hypersensitivity; Graves Ophthalmopathy; Hypersensitivity, Immediate; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis; Pemphigus; Scleroderma, Systemic
Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University)Phase 1 ClinicalSichuan University
Multiple Myeloma
Details
JWCAR129JWCAR129; JWCAR-129Phase 1 ClinicalSuzhou Yaomingjunuo Biotechnology Co Ltd
Multiple Myeloma
Details
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital)Phase 1 ClinicalChongqing Xinqiao Hospital
Multiple Myeloma
Details
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech)LCAR-BCXPhase 1 Clinical
Multiple Myeloma
Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang University
Autoimmune Diseases; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nephritis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome
Details
C-4-29Phase 1 ClinicalChongqing Precision Biotechnology Co Ltd
Carcinoma, Renal Cell; Lupus Erythematosus, Systemic; Multiple Myeloma
Details
CC-98633CC-98633Phase 1 ClinicalCelgene Corp
Multiple Myeloma
Details
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology)ClinicalWuhan BioRaid Biotechnology Co Ltd
Hematologic Neoplasms
Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)ClinicalHuazhong University Of Science And Technology
Multiple Myeloma
Details
ECAR-01ECAR-01; ECAR01ClinicalAnhui Provincial Hospital
Autoimmune Diseases
Details
CT-059XCT-059X; CT059XClinicalCARsgen Therapeutics Holdings Ltd
Leukemia, Plasma Cell; Multiple Myeloma
Details
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics)ACT-001(Acellytron Therapeutics)ClinicalAcellytron Therapeutics
Multiple Myeloma
Details
Anti-BCMA chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics)Clinical
Multiple Myeloma
Details
PD-1Ab21-BCMACAR-T (CD biopharma)CD-003; CD-203ClinicalCD (Suzhou) Biopharma Co Ltd
Multiple Myeloma
Details
BCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics)UTAA17ClinicalPersongen Biotherapeutics (Suzhou) Co Ltd
Multiple Myeloma
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Belantamab mafodotinGSK-2857916; GSK2857916ApprovedGlaxosmithkline PlcBLENREPUnited StatesMultiple MyelomaGlaxosmithkline Plc2020-08-05
Amyloidosis; Blood Protein Disorders; Bone Marrow Neoplasms; Corneal Diseases; Immunoglobulin Light-chain Amyloidosis; Lymphoma, B-Cell; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Paraproteinemias; Plasmablastic Lymphoma; Plasmacytoma
Details
Idecabtagene vicleucelbb-2121ApprovedGenetix Biotherapeutics IncAbecmaUnited StatesMultiple MyelomaCelgene Corp2021-03-26
Multiple Myeloma
Details
Zevorcabtagene AutoleucelCT-053-CARsgenApprovedCarsgen Biomedicine (Shanghai) Co Ltd赛恺泽Mainland ChinaMultiple MyelomaKaixing Life Technology (Shanghai) Co Ltd2024-02-23
Multiple Myeloma
Details
Equecabtagene AutoleucelCT-103A; CT103A; IBI-326ApprovedInnovent Biologics(Suzhou) Co Ltd, Nanjing Iaso Biotherapeutics Co Ltd福可苏, FUCASOMainland ChinaMultiple MyelomaNanjing Xunlu Biomedicine Co Ltd2023-06-30
Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Encephalitis; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Lupus Nephritis; Multiple Myeloma; Multiple Sclerosis; Muscular Diseases; Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Myositis; Neuromyelitis Optica; POEMS Syndrome; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Details
TeclistamabJNJ-64007957; JNJ-64007959; JNJ-7957ApprovedGenmab A/S, Johnson & Johnson Innovative MedicineTECAYLI, TECVAYLI, 泰立珂EUMultiple MyelomaJanssen-Cilag International Nv2022-08-23
Hematologic Diseases; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Plasmablastic Lymphoma; Smoldering Multiple Myeloma
Details
Ciltacabtagene autoleucelJNJ-4528; LCAR-B38M; JNJ-68284528ApprovedCarvykti, 卡卫荻United StatesMultiple MyelomaNanjing Legend Biotechnology Co Ltd, Janssen Research & Development Llc2022-02-28
Multiple Myeloma
Details
LinvoseltamabREGN-5458ApprovedRegeneron Pharmaceuticals IncLynozyficEUMultiple MyelomaRegeneron Ireland Designated Activity Company2025-04-23
Food Hypersensitivity; Immunoglobulin Light-chain Amyloidosis; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Renal Insufficiency, Chronic; Smoldering Multiple Myeloma
Details
ElranatamabPF‑3135; RN-613; PF-06863135ApprovedPfizer IncElrexfio, ELREXFIO™, ELREXFIOUnited StatesMultiple MyelomaPfizer Inc2023-08-14
Anemia, Hemolytic, Autoimmune; Bone Marrow Neoplasms; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Smoldering Multiple Myeloma; Spinal Cord Diseases
Details
Customer Reviews
  • C***e2026-09-03
    APC-Labeled Human BCMA (CAT# BCA-HA2H5-200tests) is well stocked with shipments typically less than 3 days after ordering. Our regional sales representative is very attentive and has been a useful resource in tracking orders when working on a tight schedule. The APC-Labeled Human BCMA works wonderfully. This is a directly conjugated material, thus no need for a secondary antibody so it can simply your experimental design and reduce the complexity of your experimental variables when designing your experiment's working range. A dilution series from their recommended 1:50, dilution sill performed well in flow cytometry well ~200 dilution (8x more dilute than recommended) and still detected positive cells at a 1:800 dilution (16-fold higher dilution than recommended) where I ended the titration series. Note- Your experimental setup may have different optimum dilutions, depending on your setup and goals. There was no non-specific binding, thus enabling minimal PBS washes and potentially allows for less cells to be utilized as some fraction will be lost each wash. I'm very pleased with the product, it will simplify assay design and reduce development time.
  • T***d2025-06-13
    Group used this product in a TE experiment on the MSD platform. Achieved a STD Curve range that was adequate for assay needs.
  • S***i2025-01-23
    We have repurchased this item dozens of time. This product is very effective for flow cytometry and we use it to help detect our BCMA CAR-T product.
  • J***y2024-10-29
    Product utilized for routine FACS flow cytometry analyses of T cells cultured in vitro. The material comes in efficient packaging, and comes in quantities that facilitate reliable mid- to long-term stock. There have not appeared to be any signs of problems with failed non-specific binding blockage. The material has proven to be reliable in performance over moderate lengths of storage time, and after experiencing some variable temperature exposure.
  • E***s2023-03-23
    Protein was easy to use. High quality allowed for titration and we could get many more tests from one vial than from other vendors. Lyophilized product was nice for stability. Availability of multiple fluorophores is nice. We ended up using biotin as to make it fit into any flow cytometry assay we wanted. Will continue to use. Has become lab standard for CAR detection by FC
  • E***n2021-09-18
    The product is used to determine the expression level of BCMA-CAR after transduction in human cells. Flow cytometry analysis was used to determine the expression of BCMA-CAR by first staining with viability dye, block the FcR, then stained with this product in 5ul of this product resuspended to manufacturer's spec, in 100ul staining volume. The samples were then labeled with Streptavidin-PECy7 and gone through flow cytometry. This product provides a good way to evaluate BCMA-CAR expression with minimum noise. Highly recommended!
  • M***t2021-09-14
    We are using the biotinylated Human BCMA for an affinity capture assay and we are really happy with the product performance. The antigen are coupled to magnetic beads in order to pull out anti-BCMA antibodies from biological matrices. We receive very high reproducibility and accuracy of results in combination with a high throughput of samples. Using these beads we obtain a very low LLOQ, which was not possible with antigens from other companies.
  • B***y2021-08-31
    The product quality at Acro is great. We have used many of their recombinant proteins for screening antibody targets. The recombinant BCMA was used for functional in vitro cytotoxicity studies. This product helped inform our current program and future studies!
  • 1***62019-09-26
    We used this product to detect the positive expression rate of LCAR-B38M product using flow cytometry. This product shows good clustering effect. It is worth to recommend to others.
  • 1***92019-10-17
    I purchased this protein for antibody screening. I performed flow cytometry to test whether this protein can bind to molecules expressed on cell surface. The results showed that some antibodies could bind to this protein. The protein quality is pretty good.
  • 1***12019-11-16
    This product was purchased mainly for detecting the positive expression rate of CAR-T cells targeting BCMA. My colleagues have tried to express and purify the protein by themselves, but it was difficult to get consistent same quality level between batches. Almost all products of Acro have rich application examples to ensure their excellent products features and reliable quality control. In addition, Acro's biotin labeling technology is particularly incredible, and the detected signal is very uniform, which makes the products excellent among similar products domestically. The only drawback is that the price is a bit expensive.
  • 1***32019-10-16
    I purchased 1mg of human BCMA-Fc antigen for screening assay. This antigen is stable and the screening results are reproducible. In addition, I used this antigen to do in house biotinylation for octet detection. The result is also very good.
  • 1***42019-10-11
    This product was purchased for animal immunization, so we need protein products with high purity and low endotoxin. ACROBio promises their proteins can do this. The high-purity BCMA protein guaranteed the success of our experiments as we expected. THANK YOU ACROBio.